메뉴 열기
메뉴 닫기
메뉴 닫기
Recently reviewed Professionals
Soo Yeon Park is a healthcare industry lawyer who advises multinational pharmaceutical, biotechnology, medical device, and e-cigarette companies on the integrated management of regulatory, intellectual property, and product risk issues throughout the lifecycle of their businesses. Leveraging her qualifications as a licensed pharmacist, attorney-at-law, and patent attorney, she provides legal advice spanning research and development, market entry, commercialization, and post-market compliance, with a focus on supporting stable and sustainable business operations in Korea.

In particular, Ms. Park has extensive experience advising global life sciences companies on core regulatory and intellectual property matters, including regulatory approvals, pricing and reimbursement, technology transactions and licensing, and patent disputes in the pharmaceutical and medical device sectors. She is recognized for her ability to assess these interrelated issues within the broader industry and regulatory framework, enabling clients to navigate complex regulatory requirements while maintaining long-term business viability.

In addition, Ms. Park advises international clients on product safety and human health risk issues arising from pharmaceuticals, medical devices, consumer healthcare products, and chemical products. Her practice includes responding to regulatory investigations, product liability and consumer claims, and related administrative, civil, and criminal proceedings. Through this work, she provides practical legal advice grounded in a comprehensive understanding of regulatory enforcement and dispute resolution in the healthcare industry.
学歴
2015 Kyung Hee University Law School - J.D.
2011 Ewha Woman’s University - B.S. in Pharmacy
LOAD MORE
経歴
2015-Present Lee & Ko
2011-2012 Hallym University Medical Center
LOAD MORE
資格/会員
2015 Association; Korean Patent Attorneys, Admitted to the Korean Patent Bar
2015 Admitted to the Korean Bar
2011 Licensed Pharmacist
LOAD MORE
言語
Korean and English
受賞実績
2026 Recognized as a "Next generation Partners" by The Legal 500 Asia Pacific 2026(Intellectual property(PATMA))
2025 Recognized as a "Next generation Partners" by The Legal 500 Asia Pacific 2025(Intellectual property(PATMA))
2024 Recognized as a "Next generation Partners" by The Legal 500 Asia Pacific 2024(Intellectual property(PATMA))
2023 Recognized as a “Rising Star” by Legal 500 (Intellectual Property)
LOAD MORE
著書/活動
Lexology Panoramic: Pharmaceutical Antitrust 2025
Life Sciences 2025 - South Korea | Global Practice Guides | Chambers and Partners (2022-2025)
LOAD MORE
Related news

ニュースレター

Seoul Administrative Court Revokes MFDS Rejection of Marketing Authorization Application for Stem Cell Therapy 2026.07.21

ニュースレター

IP Perspective Vol.4 by Lee & Ko IP & TECHNOLOGY Group 2026.04.13

受賞等

'Legal 500 Asia Pacific 2026' ranks Lee & Ko in the top tier in 16 practice areas 2026.01.15

最近の業務事例

Representation in an International Dispute Concerning a Medical Device Supply Agreement 2025.11.28

セミナー/イベント

Seminar on “Changes in the IP and Technology Protection Environment in the Era of Technological Innovation and How to Respond” 2025.11.27

メディア

[The Korea Economic Business Magazine] “The Lawyer of Lawyers” – Selected by Attorneys from Korea’s Seven Leading Law Firms 2025.08.25

ニュースレター

IP Perspective Vol.3 by Lee & Ko Intellectual Property Group 2025.08.21

最近の業務事例

Providing Successful Regulatory Support for New Product Launches by Global F&B and Alcohol Companies 2025.04.30

最近の業務事例

Establishing Approval and Intellectual Property Portfolio Strategies in Response to the Introduction of the Data Protection System under the Amended Pharmaceutical Affairs Act 2025.02.28

ニュースレター

IP Perspective Vol.2 by Lee & Ko Intellectual Property Group 2025.02.17

ニュースレター

IP Perspective Vol.1 by Lee & Ko Intellectual Property Group 2024.09.11

受賞等

'Legal 500 Asia Pacific 2024' ranks Lee & Ko in the top tier in 15 practice areas 2024.01.18

メディア

[Korean economy] The reason why we were involved in a legal dispute over "Haeundae Amso Galbijip". 2022.01.16
LOAD MORE